How is belzutifan administered?
The recommended belzutifan dosage is 120 mg administered orally once daily with or without food.
What is belzutifan used for?
Belzutifan, sold under the brand name Welireg, is a medication used for the treatment of von Hippel–Lindau disease-associated renal cell carcinoma. It is taken by mouth. The most common side effects include decreased hemoglobin, anemia, fatigue, increased creatinine, headache, dizziness, increased glucose, and nausea.
What is Von Hippel Lindau disease?
VHL disease is an inherited disorder that causes tumors and cysts to grow in certain areas of the body, including the central nervous system (including the brainstem, cerebellum, and spinal cord), retina, endolymphatic sac in the ear, adrenal glands, pancreas, kidneys, epididymis (in males), and broad ligament (in …
Are there any treatments or cures for von Hippel Lindau syndrome?
How Is Von Hippel-Lindau Syndrome (VHL) Treated? Although there is no cure for VHL, the associated tumors can be treated. Early detection and treatment of tumors significantly improves a patient’s diagnosis. Left untreated, VHL may result in blindness, permanent brain damage, or death.
Who makes Belzutifan?
The study was funded by Merck, which makes belzutifan. After 18 months, 49% of the participants had a partial response.
Where is Lenvima made?
EISAI LAUNCHES LENVIMA® (LENVATINIB) IN CHINACOMMENCES PROVIDING THE FIRST NEW THERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN CHINA IN ALMOST A DECADE. Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that its Chinese subsidiary Eisai China Inc.
How long do people live with VHL?
Despite recent advances in clinical diagnosis and management, life expectancy for VHL patients remains low at 40–52 years.
How do I know if I have VHL?
How is VHL diagnosed? The only way to diagnose VHL is with genetic testing. Nearly all people with VHL will be found to have a genetic mutation in their VHL gene once tested. There are no universal guidelines regarding who should be screened for VHL.
When is Belzutifan available?
On August 13, 2021, the US Food and Drug Administration (FDA) approved Belzutifan [pronounced bell-ZOO-ti-fan] (Welireg) for the treatment of renal cell carcinoma (RCC), pancreatic neuroendocrine tumors (pNET) and hemangioblastomas (HB) in adult VHL patients. The medication is now available to be prescribed in the US.